What's Happening?
Doximity, a digital platform for U.S. medical professionals, is significantly increasing its investment in artificial intelligence (AI) in 2026. The company aims to enhance its AI capabilities to become a leading platform for doctors. This includes scaling
its clinical AI suite with tools like the ambient notetaking tool Scribe and the clinical AI assistant Ask. Doximity has also formed partnerships with Aledade and Photon Health to expand its reach and capabilities. Despite these efforts, Wall Street has shown caution, with Doximity's shares dropping 24% following its earnings call. The company's fiscal year 2027 revenue guidance fell below Wall Street expectations, contributing to the cautious outlook.
Why It's Important?
Doximity's increased focus on AI represents a strategic move to capture a larger share of the growing AI market in healthcare. By enhancing its AI tools, Doximity aims to improve physician workflow and decision-making, potentially leading to better patient outcomes. The partnerships with Aledade and Photon Health could expand Doximity's influence in primary care and e-prescribing, respectively. However, the company's financial performance and stock market reaction highlight the challenges it faces in convincing investors of its long-term growth potential. The competitive landscape, including legal disputes with OpenEvidence, further complicates Doximity's path forward.
What's Next?
Doximity plans to continue its AI development, with a focus on integrating AI tools into electronic health records and expanding its user base among U.S. physicians. The company is also navigating legal challenges with OpenEvidence, which could impact its reputation and market position. As Doximity rolls out new AI features, it will need to address trust and safety concerns to maintain its competitive edge. The outcome of its legal disputes and the effectiveness of its AI investments will be critical in determining its future success.
